IL273684A - Variants of beta-glucocerebrosidase for use in treating gaucher disease - Google Patents

Variants of beta-glucocerebrosidase for use in treating gaucher disease

Info

Publication number
IL273684A
IL273684A IL273684A IL27368420A IL273684A IL 273684 A IL273684 A IL 273684A IL 273684 A IL273684 A IL 273684A IL 27368420 A IL27368420 A IL 27368420A IL 273684 A IL273684 A IL 273684A
Authority
IL
Israel
Prior art keywords
glucocerebrosidase
variants
beta
gaucher disease
treating gaucher
Prior art date
Application number
IL273684A
Other languages
Hebrew (he)
Inventor
Silman Israel
Ashani Yaacov
L Sussman Joel
Khersonsky Olga
FLEISHMAN Sarel
Goldenzweig Adi
H Futerman Anthony
POKORNA Sarka
Original Assignee
Yeda Res & Dev
Silman Israel
Ashani Yaacov
L Sussman Joel
Khersonsky Olga
FLEISHMAN Sarel
Goldenzweig Adi
H Futerman Anthony
POKORNA Sarka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Silman Israel, Ashani Yaacov, L Sussman Joel, Khersonsky Olga, FLEISHMAN Sarel, Goldenzweig Adi, H Futerman Anthony, POKORNA Sarka filed Critical Yeda Res & Dev
Priority to IL273684A priority Critical patent/IL273684A/en
Priority to CA3174917A priority patent/CA3174917A1/en
Priority to CN202180026117.5A priority patent/CN115348884B/en
Priority to BR112022019510A priority patent/BR112022019510A2/en
Priority to EP21720584.8A priority patent/EP4126226A1/en
Priority to PCT/IL2021/050357 priority patent/WO2021199039A1/en
Priority to AU2021245409A priority patent/AU2021245409A1/en
Priority to US17/915,500 priority patent/US20230132790A1/en
Priority to KR1020227037779A priority patent/KR20230003492A/en
Priority to JP2022559375A priority patent/JP2023519934A/en
Priority to IL296696A priority patent/IL296696A/en
Publication of IL273684A publication Critical patent/IL273684A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
IL273684A 2020-03-29 2020-03-29 Variants of beta-glucocerebrosidase for use in treating gaucher disease IL273684A (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IL273684A IL273684A (en) 2020-03-29 2020-03-29 Variants of beta-glucocerebrosidase for use in treating gaucher disease
CA3174917A CA3174917A1 (en) 2020-03-29 2021-03-29 Variants of beta-glucocerebrosidase for use in treating gaucher disease
CN202180026117.5A CN115348884B (en) 2020-03-29 2021-03-29 Beta-glucocerebrosidase variants for the treatment of gaucher's disease
BR112022019510A BR112022019510A2 (en) 2020-03-29 2021-03-29 BETA-GLUCOCEREBROSIDASE VARIANTS FOR USE IN THE TREATMENT OF GAUCHER'S DISEASE
EP21720584.8A EP4126226A1 (en) 2020-03-29 2021-03-29 Variants of beta-glucocerebrosidase for use in treating gaucher disease
PCT/IL2021/050357 WO2021199039A1 (en) 2020-03-29 2021-03-29 Variants of beta-glucocerebrosidase for use in treating gaucher disease
AU2021245409A AU2021245409A1 (en) 2020-03-29 2021-03-29 Variants of beta-glucocerebrosidase for use in treating Gaucher Disease
US17/915,500 US20230132790A1 (en) 2020-03-29 2021-03-29 Variants of beta-glucocerebrosidase for use in treating gaucher disease
KR1020227037779A KR20230003492A (en) 2020-03-29 2021-03-29 Beta-glucocerebrosidase variants for the treatment of Gaucher disease
JP2022559375A JP2023519934A (en) 2020-03-29 2021-03-29 Variants of beta-glucocerebrosidase for use in treating Gaucher disease
IL296696A IL296696A (en) 2020-03-29 2021-03-29 Variants of beta-glucocerebrosidase for use in treating gaucher disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL273684A IL273684A (en) 2020-03-29 2020-03-29 Variants of beta-glucocerebrosidase for use in treating gaucher disease

Publications (1)

Publication Number Publication Date
IL273684A true IL273684A (en) 2021-09-30

Family

ID=77989484

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273684A IL273684A (en) 2020-03-29 2020-03-29 Variants of beta-glucocerebrosidase for use in treating gaucher disease

Country Status (1)

Country Link
IL (1) IL273684A (en)

Similar Documents

Publication Publication Date Title
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
NZ624963A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PL3599237T3 (en) Pharmaceutical composition of the glucosylceramide synthase inhibitor eliglustat for the treatment of gaucher's disease comprising adjusting the individual therapeutical dose to the p450 metabolism of the patient
EP2429411A4 (en) Methods and devices to treat diseased or injured musculoskeletal tissue
RU2018145985A (en) ACTIVIN-ACTRII ANTAGONISTS AND THEIR APPLICATION FOR TREATMENT OF BONE TISSUE DISORDERS AND OTHER DISORDERS
CO6660423A2 (en) Compositions and methods to treat gaucher disease
EP4146633A4 (en) Composition for use in the treatment of apol1-associated disease
EA201590166A8 (en) COMBINED THERAPY FOR THE TREATMENT OF SCATTERED SCLEROSIS
IL207559A0 (en) Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease
IL216737A0 (en) Formulations for the treatment of deep tissue pain
EP2381956A4 (en) Treatment of soft tissue injury using hyaluronic acid and botulinum toxin
EP2274411A4 (en) Xanthohumol compositions and methods for treating skin diseases or disorders
IL260078B (en) Therapy for use for the treatment of gaucher's disease
HK1152649A1 (en) Method for the identification of patients in need of therapy having minor cognitive disorders and the treatment of such patients
EA201200428A1 (en) COMPOSITION AND METHOD FOR TREATING OBESITY
EP2301561A4 (en) Pharmaceutical composition for treatment of dry eye and/or corneal/conjunctival disorders
IL290726A (en) Use of brazikumab to treat crohn's disease
SG11202007082PA (en) Composition used for therapeutic treatment of skin disease
EP4157255A4 (en) Treatment of coronavirus
IL273684A (en) Variants of beta-glucocerebrosidase for use in treating gaucher disease
IL209145A0 (en) Narcotic emulsion formulations for treatment of surgical pain
IL304628A (en) Treatment of skin disorders
EP4213855A4 (en) TREATMENT OF NF-kB-MEDIATED DISEASE
SG11202108480UA (en) Compositions useful in treatment of krabbe disease
IL310131A (en) Prc-210 for use in the treatment of acute tissue injury